The Food and Drug Administration (FDA) approved enzalutamide or patients with metastatic castration-sensitive prostate cancer (mCSPC).

FDA previously approved enzalutamide for patients with castration-resistant prostate cancer.

Efficacy was investigated in ARCHES, a trial enrolling 1150 patients with mCSPC randomised (1:1) to receive either enzalutamide orally 160 mg once daily (N=574) or placebo orally once daily (N=576).

All patients received a GnRH analog or had a prior bilateral orchiectomy.

The main efficacy outcome measure was radiographic progression-free survival (rPFS).

Based on blinded independent central review, rPFS was defined as the time from randomisation to radiographic disease progression at any time or death within 24 weeks after drug discontinuation.

Radiographic disease progression was defined by identification of 2 or more new bone lesions on a bone scan with confirmation (Prostate Cancer Working Group 2 criteria) and/or progression in soft tissue disease.

Time to new antineoplastic therapy was an additional endpoint.

Median rPFS was not reached (NR) in the enzalutamide arm compared to 19.4 months (95% CI: 16.6, NR) in the placebo arm (HR 0.39; 95% CI: 0.30, 0.50; p<0.0001).

A statistically significant improvement was also reported on the enzalutamide arm compared to placebo in time to initiation of a new antineoplastic therapy (HR 0.28; 95% CI: 0.20, 0.40; p<0.0001).

Overall survival (OS) data were not mature at the time of rPFS analysis.

The most common adverse reactions (≥ 5%) that occurred more frequently (≥ 2% over placebo) in enzalutamide-treated patients in ARCHES were hot flush, asthenia/fatigue, hypertension, fractures, and musculoskeletal pain.

The recommended dose is 160 mg (four 40 mg capsules) administered orally once daily, with or without food.

Source: The Food and Drug Administration (FDA)